The value of the nucleic acid testing market is projected to grow to US$ 5.25 Bn with an estimated CAGR of ~7.3% by 2028
.jpg
"The Global Nucleic Acid Testing Market 2018-2028 (USD Billion)")
Nucleic acid testing is a technique for the detection of viral DNAs and RNAs in a blood sample. This technique is highly sensitive and specific for viral nucleic acids, and is widely used to detect HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. It is among the most convenient and widely preferred tests, thus highly is utilized disease diagnostics and monitoring. Nucleic acid testing also reduces the window period through direct detection of viral nucleic acid sequences and helps in prevention of transfusion of infected blood component and therefore exposure to life-threatening diseases.
According to data published by the UNAIDS, in 2018, 37.9 million people are already suffering from HIV and 1.7 million new HIV cases has been found, globally. As a result, the demand for nucleic acid testing is rising, thereby significantly fueling the global market growth. Additionally, according to the World Health Organization (WHO), in 2018, around 500 million people were infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) worldwide. Thus, requirement for nucleic acid testing has been considerably increasing, which further contributes to the market growth.
Growing precision in nucleic acid testing technology boosting the market growth
There has been a consistent growth in demand for novel nucleic acid testing methods in context to sample extraction, preparation, testing and amplification. Moreover, various research and development activities striving to introduce advanced testing solutions are further contributing to the growth of nucleic acid testing market globally. For instance, in September 2018, the National Institute of Singapore invented a new point of care testing for infectious diseases diagnostic imaging device for nucleic acid testing. This device is extremely sensitive, fast & accurate, and thus is anticipated to witness positive demand in the years to come. However, high cost associated with this test, along with limited reimbursement are some factors likely to hamper the market growth.
Rising incidence of chronic disease such as cancer and genetic mutations to witness higher penetration of nucleic acid tests
Currently, nucleic acid testing is widely used in oncology. Genetic factors such as inherited mutations (changes in DNA sequences) may cause cancer risk. In this case, nucleic acid testing can identify the inherited mutations and therefore may help in prevention of the risk of cancer incidence. Hence, this factor is likely to boost the global nucleic acid testing market.
North America anticipated to retain its stronghold on the global market
Geographically, the nucleic acid testing market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa. However, North America is likely to hold the largest market share through the forecast period. Increasing investment in R&D and building healthcare infrastructure are some supporting the future growth of nucleic acid testing market. Asia Pacific is expected to be the fastest growing market for nucleic acid testing owing to rapidly developing healthcare industry and rising awareness regarding diagnosis and management of life-threatening diseases. Evolving skills of medical professionals in the region is also among the key attributes to the progress of Asia Pacific market during the forecast period.
Key Market Players
- Abbott Laboratories
- Becton Dickinson and Company
- Illumina, Inc
- ELITechGroup SAS
- Siemens Healthcare Private Limited
- CooperSurgical, Inc
- PerkinElmer Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Grifols, S.A.
nucleic acid testing market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2028 |
| Study Period | 2018-2028 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2028 | US$ 5.25 Bn |
| Growth Rate | CAGR of 7.3 % during 2021-2028 |
| Segment Covered | by Product Type, Indication, End-User, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
| Key Players Profiled | Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Illumina, Inc., Novartis Ag, Qiagen N.V., Quest Diagnostics Incorporated, Siemens Ag, and Tecan Group Ltd., among others. |
Key Segment Of The nucleic acid testing market
Product Type, (USD Million)
o Nucleic Acid Test Kits
• Transcription-Mediated Amplification (TMA)
• Polymerase Chain Reaction (PCR)
• Ligase Chain Reaction (LCR)
• Whole Genome Sequencing
o Consumables
Indication, (USD Million)
• Infectious diseases
• Cancer
• Forensic Testing
• Others
End-user, (USD Million)
• Hospitals
• Pathology laboratories
• Research Institutes
• Clinics
Regional Overview, (USD Million)
North America
• US
• Canada
Europe
• Germany
• France
• UK
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
South America
• Mexico
• Brazil
• Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
The major contenders in the global market are Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Illumina, Inc., Novartis Ag, Qiagen N.V., Quest Diagnostics Incorporated, Siemens Ag, and Tecan Group Ltd., among others.
The segments are covered in the nucleic acid testing market by Product Type, Indication, End-User, Regions.
To get latest version of nucleic acid testing market report can be obtained on demand from the website.